• Ascletis Pharma submitted an investigational new drug application to the U.S. FDA for ASC30_39 FDC to treat obesity.
• The once-daily oral tablet combines GLP-1 receptor agonist ASC30 with selective amylin receptor agonist ASC39.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20261111-12408103), on November 11, 2026, and is solely responsible for the information contained therein.